Conditions

Cerebral Palsy

Cerebral palsy (CP) is a disorder of movement, muscle tone and/or posture that begins at or around birth. It is the most common physical disability in childhood affecting up to 1 in 500 newborns and over 17 million people worldwide.

Physical disability of CP is diverse and can range from muscle weakness to complete lack of movement. In addition to physical disability, children with CP are likely to have other medical conditions and impairments. Intellectual impairment, behavior disorders, sleep disorders and others are common.

Although CP is a life-long condition without a known cure, early treatment and intervention can improve symptoms and the quality of life of those who have the condition. The conventional approach includes physical therapy, occupational therapy, massage therapy, speech therapy, behavioral/cognitive therapies, surgery, etc. Medications are also prescribed to CP patients in order to reduce symptoms and treat other medical conditions. Despite these various treatment options, the conventional approach to treating CP is limited and often does not produce significant improvement in symptoms or quality of life. The search for more effective treatment options continues.

Stem cell therapy has been found to be one of the most effective treatments for children with neurological disorders including CP. Several studies have demonstrated the effectiveness of stem cell therapy in improving gross motor function, muscle tone, spasticity, development and quality of life in patients with CP. Stem cell therapy has also been shown to reduce brain inflammation, increase whole brain connectivity and activate motor regions of the brain.

Stem cell therapy using various different cell types and tissue types such as umbilical cord derived mesenchymal stem cells (UCMSCs), bone marrow derived mononuclear cells (BMMNCs) and umbilical cord blood (UCB) have been shown to be safe and well tolerated. Many studies use umbilical cord blood as the intervention due to its rich content of diverse cell types including various stem cells and progenitor cells. Evidence suggests that these cells produce signaling molecule to modulate the immune system and facilitate functional brain repair.

Based on early human clinical trials there appears to be a strong argument for the safe and effective use of stem cell therapy in the treatment of CP. While we wait for phase II/III trials the current data is encouraging and supports use of stem cell therapy in the clinical setting.

Year Author No. of Patients Delivery and Cell Type Follow-up Safety Outcome Efficacy Outcome
2018 Huang et al 27 IV UC-MSCs 24 months No adverse immunological response and no SAEs. Common AEs included diarrhea and URI. No adverse changes in lab tests. Improvements in gross motor and comprehensive functions measured by GMFM-88 and CFA. Changes in electrophysiology of less diffuse slow waves on MRI.
2017 Sun et al 63 IV UCB 12 months No SAEs. One patient experienced infusion related hives and low grade fever to both placebo and UCB treatment. UCB above the median cell dose demonstrated statistically significant and clinically meaningful improvement in GMFM-66 and PDMS-2 after 1 year post treatment. MRI showed significant improvement in whole brain connectivity.
2015 Romanov et al 80 IV UCB 36 months No SAEs. No acute or delayed AES reported. Significant improvements in neurological status, physical capacity and cognitive functions in patients who received >4 infusions. Overall improvements in neurological, physical activity and/or intellectual development were seen in approximately 70% patients.
2015 Kang et al 36 IV UCB 6 months No SAEs reported. Significant Improvements in muscle strength and gross motor skills. F-FDG PET scans showed increased metabolism in motor regions of the brain after UCB infusion and indicate an activation of motor function.
2013 Min et al 96 IV UCB 6 months Incidence of SAEs did not differ between groups. Pneumonia and irritability were most frequent AEs in treatment group. Improvements in motor, social and cognitive functions measured by GMPM, BSID-II, GMFM., WeeFIM. The pUCB group showed greater motor function improvements, greater cognitive outcomes and had increased FA on MRI.
2012 Lee et al 20 IV CB-MNCs 6 months Minimal adverse events which were controlled with medication and intravenous hydration. 25% of children had partial improvements in neurodevelopment evaluations tests after a single IV of CB-MNCs. Only 10% of patients demonstrated improved perfusion. Neurodevelopment improvements were significant in patients with hemiplegia or diplegia compared to quadriplegia.

* IV = intravenous, UCB = umbilical cord blood, CB-MNCs = cord blood derived mononuclear cells, AEs= adverse events, SAEs = serious adverse events, GMPM = gross motor performance measure, GMFM-88 = gross motor function measure, CFA = comprehensive functional assessment, PDMS-2 = Peabody development motor scales, F-FDG PET = Fluorodeoxyglucose positron emission tomography, BSID-II = Bayley scales of infant development, WeeFIM =Wee functional independence measure, FA = fractional anisotropy.

Proven Benefits From Early Human Clinical Trials of stem Cell Therapy in Cerebral Palsy (CP)

  • Improvement in gross motor abilities in lying and rolling, sitting, crawling and kneeling, standing and walking, running, and jumping. (Huang et al, Sun et al, Novak et al, Min et al)
  • Improvement in comprehensive function in cognizance, language competence, self-care, motor function, and social adaptability.(Huang et al)
  • Improvement in muscle tone and muscle strength. (Romanov et al, Kang et al)
  • Improvement in neurological and physical status.(Romanov et al)
  • Improvement in intellectual development and mental status.(Romanov et al)
  • Decreased brain inflammation and inflammatory markers in blood. (Kang et al)
  • Increased whole brain connectivity and metabolism in motor regions of brain. (Sun et al, Kang et al)

Specific Conclusions From Selected Studies:

“The results of the study indicated that hUCB-MSC infusion with basic rehabilitation was safe and effective in improving gross motor and comprehensive functions in children with CP.”

  • A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy (Huang et al 2018)

“Results of this study suggest that appropriately dosed autologous cord blood (ACB) infusion improves brain connectivity and gross motor function in young children with CP.”

  • Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial (Sun et al 2017)

“Stem cells appeared to induce short-term improvements in motor skills.

  • Concise Review: Stem Cell Interventions for People with Cerebral Palsy: Systematic Review with Meta-Analysis (Novak et al 2016)

“The results confirm that multiple intravenous infusions of allogeneic AB0/Rh-identical UCB cells may be a safe and effective procedure and could be included in treatment and rehabilitation programs for juvenile patients with cerebral palsy.”

  • Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy (Romanov et al 2015)

“In this trial, treatment with UCB alone improved motor outcomes and induced systemic immune reactions and anti-inflammatory changes in the brain. Generally, motor outcomes were positively correlated with the number of UCB cells administered: a higher number of cells resulted in better outcomes.”

  • Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy (Kang et al 2015)

“In conclusion, UCB treatment ameliorated motor and cognitive dysfunction in children with CP undergoing active rehabilitation, accompanied by structural and metabolic changes in the brain.”

  • Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double-blind, randomized, placebo-controlled trial (Min et al 2013)

“Autologous CB infusion is safe and feasible, and has yielded potential benefits in children with CP.”

  • Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. (Lee et al 2012)

For additional information on stem cell therapy in cerebral palsy and more details regarding these studies please visit our Research Archive.

Exosomes have potential significant therapeutic effects in regenerative medicine, anti-aging and chronic disease. Click here to learn more about Exosome Therapy.

Brought to you by:

Ahvie Herskowitz, MD, President of ACAM
Director of Anatara Medicine
Founder of San Francisco Stem Cell Treatment Center
Clinical Professor of Medicine at UC San Francisco (2014)
(Read Dr. Herskowitz’s Bio Here)

Follow Us





Disclaimer

The contents of Understanding Stem Cells, such as text, graphics, images and other materials are for educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis or treatment. You are encouraged to confirm any information on this website with other sources and review all information regarding any medical condition or treatment with your physician.

View our Terms and Conditions